HC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS)

HC Wainwright reissued their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.

Several other research analysts have also recently weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. Stifel Nicolaus assumed coverage on Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 target price on the stock. Stephens assumed coverage on Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target for the company. Finally, William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Pyxis Oncology Price Performance

Shares of PYXS opened at $1.90 on Thursday. The company’s 50-day moving average is $3.64 and its 200-day moving average is $3.61. The firm has a market capitalization of $112.99 million, a PE ratio of -1.84 and a beta of 1.27. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Fullcircle Wealth LLC bought a new stake in Pyxis Oncology during the second quarter worth about $40,000. Intech Investment Management LLC acquired a new position in shares of Pyxis Oncology in the 3rd quarter valued at approximately $55,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology during the 3rd quarter worth approximately $58,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $65,000. Finally, MetLife Investment Management LLC increased its stake in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after acquiring an additional 5,484 shares during the last quarter. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.